Señales en vivo de VIRX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	32 999.00
Volumen promedio	114 843
Capitalización de mercado	31.82M
EPS	$0 ( 2024-03-11 )
Próxima fecha de ganancias	( $-0.350 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0.00700 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Burcar Melody	Sell	80 000	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	47 500	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	33 250	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	100 000	Stock Option (Right to Buy)
2024-03-12	Rothera Mark	Buy	475 000	Stock Option (Right to Buy)

INSIDER POWER
67.59
Last 97 transactions
Buy: 4 797 715 \| Sell: 606 024

Volumen Correlación

Largo: -0.20 (neutral)

Corto: 0.66 (moderate)

Signal:(50.069) Neutral

Sunesis Pharmaceuticals Correlación

10 Correlaciones Más Positivas
TOI	0.962
TIL	0.958
ONCS	0.958
VSTA	0.948
IMRX	0.943
TRVI	0.943
LTRPA	0.942
TFFP	0.94
CGO	0.938
EBIZ	0.937

10 Correlaciones Más Negativas
AMRB	-0.931
DCRC	-0.93
TEDU	-0.926
CCRC	-0.915
RMRM	-0.915
IBEX	-0.907
BRQS	-0.906
SRAC	-0.904
PBFS	-0.903
CYAN	-0.902

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sunesis Pharmaceuticals Correlación - Moneda/Commodity

0.23
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.05
( neutral )

Sunesis Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-492 000 (0.00 %)
EPS:	$-1.320

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-492 000 (0.00 %)
EPS:	$-1.320

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-210 000 (0.00 %)
EPS:	$-1.320

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Sunesis Pharmaceuticals

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.